Stefan Kostense

Evidence that human CD8+CD45RA+CD27– cells are induced by antigen and evolve through extensive rounds of division (1999)

Hamann, Dörte, Kostense, Stefan, Wolthers, Katja C., Otto, Sigrid A., Baars, Paul A., Miedema, Frank, ...

We recently showed that circulating human CD8+ effector cells have a CD45RA+CD27– membrane phenotype. In itself this phenotype appeared to pose a paradox: CD45RA, a marker expressed by...

Longitudinal Phenotypic Analysis of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes: Correlation with Disease Progression

Ogg, Graham S., Kostense, Stefan, Klein, Michel R., Jurriaans, Suzanne, Hamann, Dörte, McMichael, Andrew J., ...

Few studies have examined longitudinal changes in human immunodeficiency virus type 1 (HIV)-specific cytotoxic T lymphocytes (CTL). To more closely define the natural history of HIV-specific CTL, we...

Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity

Vogels, Ronald, Zuijdgeest, David, Van Rijnsoever, Richard, Hartkoorn, Eric, Damen, Irma, De Béthune, Marie-Pierre, ...

Replication-deficient human adenovirus type 5 (Ad5) can be produced to high titers in complementing cell lines, such as PER.C6, and is widely used as a vaccine and gene therapy vector. However,...

Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors

Sprangers, Mieke C., Lakhai, Wandena, Koudstaal, Wouter, Verhoeven, Marielle, Koel, Björn F., Vogels, Ronald, ...

The presence of various levels of anti-adenovirus serotype 5 (Ad5)-neutralizing antibodies in humans is thought to contribute to the inconsistent clinical results obtained so far in diverse gene...

Neutralizing Antibodies and CD8+ T Lymphocytes both Contribute to Immunity to Adenovirus Serotype 5 Vaccine Vectors

Sumida, Shawn M., Truitt, Diana M., Kishko, Michael G., Arthur, Janelle C., Jackson, Shawn S., Gorgone, Darci A., ...

The high prevalence of preexisting immunity to adenovirus serotype 5 (Ad5) in human populations will likely limit the immunogenicity and clinical utility of recombinant Ad5 vector-based vaccines for...

Longitudinal Phenotypic Analysis of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes: Correlation with Disease Progression

Ogg, Graham S., Kostense, Stefan, Klein, Michel R., Jurriaans, Suzanne, Hamann, Dörte, McMichael, Andrew J., ...

Few studies have examined longitudinal changes in human immunodeficiency virus type 1 (HIV)-specific cytotoxic T lymphocytes (CTL). To more closely define the natural history of HIV-specific CTL, we...

Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity

Vogels, Ronald, Zuijdgeest, David, Van Rijnsoever, Richard, Hartkoorn, Eric, Damen, Irma, De Béthune, Marie-Pierre, ...

Replication-deficient human adenovirus type 5 (Ad5) can be produced to high titers in complementing cell lines, such as PER.C6, and is widely used as a vaccine and gene therapy vector. However,...

Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors

Sprangers, Mieke C., Lakhai, Wandena, Koudstaal, Wouter, Verhoeven, Marielle, Koel, Björn F., Vogels, Ronald, ...

The presence of various levels of anti-adenovirus serotype 5 (Ad5)-neutralizing antibodies in humans is thought to contribute to the inconsistent clinical results obtained so far in diverse gene...

Neutralizing Antibodies and CD8+ T Lymphocytes both Contribute to Immunity to Adenovirus Serotype 5 Vaccine Vectors

Sumida, Shawn M., Truitt, Diana M., Kishko, Michael G., Arthur, Janelle C., Jackson, Shawn S., Gorgone, Darci A., ...

The high prevalence of preexisting immunity to adenovirus serotype 5 (Ad5) in human populations will likely limit the immunogenicity and clinical utility of recombinant Ad5 vector-based vaccines for...